Last reviewed · How we verify
r-HuEPO
r-HuEPO is a recombinant form of human erythropoietin that stimulates red blood cell production.
r-HuEPO is a recombinant form of human erythropoietin that stimulates red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy.
At a glance
| Generic name | r-HuEPO |
|---|---|
| Also known as | NeoRecormon |
| Sponsor | Sunnybrook Health Sciences Centre |
| Drug class | erythropoiesis-stimulating agent |
| Target | erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Nephrology |
| Phase | Phase 3 |
Mechanism of action
r-HuEPO works by binding to the erythropoietin receptor on the surface of red blood cell precursors, triggering a cascade of signaling events that ultimately lead to increased red blood cell production. This can help to alleviate anemia in patients with chronic kidney disease or those undergoing chemotherapy. However, the increased red blood cell mass can also increase the risk of thrombotic events.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia associated with chemotherapy
Common side effects
- Thrombosis
- Headache
- Fatigue
- Nausea
Key clinical trials
- A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (PHASE3)
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (PHASE3)
- Assessment of BHB Concentration Agreement Among Sampling Locations and the Impact of Ketosis on EPO, and More (NA)
- Vafseo Outcomes In-Center Experience (PHASE3)
- A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (PHASE3)
- Patient Blood Management in Cardiac Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- r-HuEPO CI brief — competitive landscape report
- r-HuEPO updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI